AI-driven smart pharmacology

Abstract

With the progress of digital technology and innovative drug R&D, machine learning and data-driven algorithms have been increasingly used to support the core work of pharmaceutical areas such as new drug discovery, drug reuse and drug supervision, etc. A new concept of "Smart Pharmacology" has gradually grown into a system with rich connotations and comprehensive coverage, and the related applications and industrial chain have high prospects for development. The so-called "Smart Pharmacology" mainly uses big data, cloud computing, AI, IoT, 5G, Blockchain and other forefront digital technologies to provide whole-process, information-based, intelligence-driven solutions for various scenarios in the pharmacy sectors, including new drug development, drug molecular design, hospital drug management, clinical drug decision support, modernization of traditional medicine, pharmacy informatization, drug regulation and other broad areas, with a wide range covering drug discovery, production, supply, circulation, procurement, allocation and monitoring. In fact, the emergency of smart pharmacology provides a comprehensive and optimized path for modernizing the whole life cycle management of drugs and instills new vitality into the development of modern pharmacy.

References

[1] Su Xian , Wang Haixue , Zhao Nan , Wang Tao , Cui Yimin . Trends in innovative drug development in China. Nat Rev Drug Discov. 2022;21(10):709–710. https://doi.org/10.1038/d41573-022-00077-3.

[2] Paul D , Sanap G , Shenoy S , Kalyane D , Kalia K , Tekade RK . Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80–93. https://doi.org/10.1016/j.drudis.2020.10.010. https://www.drugs.com/fda-approval-process.html. See also, I.V. Hinkson, B. Madej, E.A. Stahlberg, Accelerating therapeutics for opportunities in medicine: a paradigm shift in drug discovery Front Pharmacol, 2020 Jun 30;11:770. doi: 10.3389/fphar.2020.00770. eCollection 2020.

[3] Su Xian , Wang Haixue , Zhao Nan , Wang Tao , Cui Yimin . Trends in innovative drug development in China. Nat Rev Drug Discov. 2022;21(10):709–710. https://doi.org/10.1038/d41573-022-00077-3.

[4] Tang W , Huang Y , Zhou D , et al. Evolving drug regulatory landscape in China: a clinical pharmacology perspective. Clin Transl Sci. 2021; 14 (4): 1222- 1230. Epub 2021 Feb 23.

[5] Chenthamarakshan Vijil , et al. Accelerating drug target inhibitor discovery with a deep generative foundation model. Sci Adv. 2023; 9: eadg7865.

[6] Chinese Society for Artificial Intelligence. China AI White Paper Series on AI and Drug Discovery; 2022. https://www.digitalelite.cn/h-nd-5520.html.

[7] Cyranoski D . AI drug discovery booms in China. Nat Biotechnol. 2021;39:900–902. https://doi.org/10.1038/s41587-021-01016-0.

[8] Arshadi Arash Keshavarzi , Webb Julia , Salem Milad , et al. Artificial intelligence for COVID-19 drug discovery and vaccine development. Sec. Medicine and Public Health Front. Artif. Intell. 2020;3:2020. https://doi.org/10.3389/frai.2020.00065.

[9] Delijewski Marcin , Haneczok Jacek . AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate. Medicine in Drug Discovery. 2021;9. https://doi.org/10.1016/j.medidd.2020.100077.

[10] Chan HCS , Shan H , Dahoun T , Vogel H , Yuan S . Advancing drug discoveryvia artificial intelligence. Trends Pharmacol Sci. 2019; 40: 592- 604.

[11] Bagabir Sali Abubaker , Ibrahim Nahla Khamis , Bagabir Hala Abubaker , Ateeq Raghdah Hashem . Covid-19 and Artificial Intelligence: genome sequencing, drug development and vaccine discovery. Journal of Infection and Public Health. 2022; 15(Issue 2):289–296. https://doi.org/10.1016/j.jiph.2022.01.011.

[12] Choudhury Avishek , Asan Onur . Role of Artificial Intelligence in Patient Safety Outcomes: Systematic Literature Review. 2020. https://doi.org/10.2196/18599. Jul 24.

[13] Chen Zhaoyi , Liu Xiong , Hogan William , Shenkman Elizabeth , Jiang Bian . Applications of artificial intelligence in drug development using real-world data. Drug Discov Today. 2021;26(Issue 5):1256–1264. https://doi.org/10.1016/j.drudis.2020.12.013.. Sci Adv

[14] Li H , Fan Y . Early prediction of alzheimer's disease dementia based on baseline hippocampal MRI and 1-year follow-up cognitive measures using deep recurrent neural networks. In: IEEE 16th International Symposium on Biomedical Imaging (ISBI 2019). 2019: 368- 371. Venice, Italy, 2019.

[15]

[16] Kudina Olya , Regulating AI in Health Care The Challenges of Informed User Engagement, https://doi.org/10.1002/hast.1263..

[17] Xu Xue , Yang Kuo , Zhang Feilong , et al. Identification of herbal categories active in pain disorder subtypes by machine learning help reveal novel molecular mechanisms of algesia. Pharmacol Res. 2020; 156: 104797.

[18] Meng XR , Wen CB . A review on artificial intelligence in TCM. Journal of Chinese Medicine Clinics. 2018;10(22):143–145. https://doi.org/10.1142/S0192415X21500622. Wang Y, Shi X, Li L, Efferth T, Shang D. The Impact of Artificial Intelligence on Traditional Chinese Medicine. Am J Chin Med. 2021;49(6): 1297-1314.

[19] Li ZY , Li PW , Gao XY , Sun Z , Ma L , Cui ZS . Focused topics and trend analysis on artificial intelligence medical device technology. China Medical Devices. 2018;15(7): 136–145. Y. Yao, Z. Wang, L. Li, "An ontology-based artificial intelligence model for medicine sideffect prediction: taking traditional Chinese medicine as an example," Vol. 2019, Article ID 8617503, 7 pages, 2019.

[20] Bu Fengjiao , Sun Hong , Li Ling , et al. Artificial intelligence-based internet hospital pharmacy services in China: perspective based on a case study. Front Pharmacol. 2022;13. https://doi.org/10.3389/fphar.2022.1027808, 09 November 2022, Sec. Drugs Outcomes Research and Policies.

[21] ICMRA. Informal innovation network horizon scanning assessment report. Artif Intell; 2021. https://www.icmra.info/drupal/sites/default/files/2021-08/horizon_scanning_report_artificial_intelligence.pdf;. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, Junaid T, Bostic T. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature. Pharmaceut Med. 2022 Oct;36(5):295-306. doi: 10.1007/s40290-022-00441-z.

RIGHTS & PERMISSIONS

2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).